Skip to content

    Concord Biotech Limited

    CONCORDBIOGood
    Healthcare·14 Nov 2025
    Management Summary

    Concord Biotech reported a subdued Q2 FY26 primarily due to temporary timing issues, including a delay in CDSCO written confirmations for EU exports and the deferment of a Middle East government tender. Despite the YoY revenue dip, underlying unit economics remain strong with adjusted EBITDA margins at 41%. Management expressed high confidence in a stronger H2 FY26 as deferred shipments resume and the new injectable facility at Valthera begins to scale.

    Highlights

    7

    • Revenue for Q2 FY26 stood at ₹247 crores, representing a 20% YoY decline but a 21% QoQ growth.

    • H1 FY26 Revenue reached ₹451 crores compared to ₹526 crores in H1 FY25, impacted by regulatory and geopolitical delays.

    • Reported EBITDA margin was 36%; however, excluding injectable facility start-up costs, the comparable EBITDA margin stood at 41%.

    • PAT for Q2 FY26 was ₹63 crores, with H1 FY26 PAT at ₹107 crores (24% margin).

    • API business contributed ₹345 crores to H1 revenue, while Formulations contributed ₹106 crores.

    • Management identified ₹40-45 crores in deferred revenue due to CDSCO renewal delays (₹20-25 cr) and Middle East tender deferment (₹20 cr).

    • Long-term guidance of 25% CAGR remains intact, supported by new injectable capacity and CDMO opportunities.

    What Changed3

    vs Q3 FY26

    Guidance items6 → 4 (-2)Risks discussed4 → 3 (-1)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹247 Cr-20%YoY
    2. 02EBITDA₹88 Cr+44%QoQ
    3. 03EBITDA Margin36%
    4. 04PAT₹63 Cr
    5. 05PAT Margin24%

    Segment breakdown

    • API Business₹345 Cr38.2%
    • Formulation Business₹106 Cr11.8%
    • Domestic Business₹247 Cr27.4%
    • Export Business₹204 Cr22.6%
    Donut· Share of H1 Revenue

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Long-term CAGR
    25%
    		High
    Revenue
    H2 Performance
    Higher than H2 FY25
    		Medium
    Other
    Immunosuppressant Revenue Contribution
    Below 70%
    		Medium
    Capacity
    Injectable Facility Revenue Potential
    ₹400-600 crores
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Regulatory Delays (CDSCO)

    Renewal of Written Confirmation for EU exports was delayed by months, impacting Q2 shipments. — Both acknowledged

    medium

    Geopolitical Conflict (Middle East)

    A government supply contract in the Middle East was deferred due to regional uncertainties and ongoing conflict. — Management acknowledged

    medium

    US Tariff Uncertainties

    Procurement patterns shifted temporarily but returned to normal after clarification that tariffs don't apply to generic drugs. — Management downplayed

    low

    Areas of Evasion(1)

    • Exact split of indirect API sales to the US market via domestic formulators.

    Q&A highlights

    3

    “On account of the written confirmation, the total amount was close to around INR 20 crores to INR 25 crores... On account of the Middle East tender, that amount also stood at around INR 20 crores.”

    Confirms that the revenue dip was due to specific, recoverable timing issues rather than structural demand loss.

    asked by Chintan Sheth, Girik Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Regulatory and Geopolitical Headwinds Impact Q2

    Concord Biotech's Q2 FY26 revenue of ₹247 crores was significantly impacted by a delay in receiving Written Confirmation from CDSCO for EU exports, which deferred ₹20-25 crores of revenue into Q3. Additionally, a ₹20 crore government tender for the Middle East was deferred due to regional conflict. Management clarified that these are timing difference📎s rather than business losses, with EU shipments already resuming in November 2025.

    02

    Margin Resilience Amidst Facility Start-up Costs

    While reported EBITDA margins were 36%, the company highlighted that excluding the start-up costs of the new injectable facility at Valthera, margins remained robust at 41%. This adjusted figure is consistent with historical performance. Management expects margins to strengthen as the injectable facility ramps up utilization from its current 24% level.

    03

    Strategic Expansion into Injectables and CDMO

    The newly commissioned injectable facility is currently targeting the Indian market with branded generics, with plans to enter emerging markets in 12-18 months. The facility has a long-term revenue potential of ₹400-600 crores. In the CDMO segment, Concord is actively engaged with innovator companies for commercial molecules, viewing this as a significant long-term growth driver.

    04

    Diversification of Product Portfolio

    Concord is actively working to reduce its dependence on immunosuppressants, which currently account for 76% of revenue. The goal is to bring this below 70% in the next 2-3 years by scaling non-immuno products like Nystatin (anti-infective) and oncology APIs. Most new product development is now focused on the non-immuno segment to capture a larger market share.

    05

    Capacity Utilization and Infrastructure Readiness

    The company provided detailed H1 utilization rates: Unit-1 (Dholka) at 76%, Valthera (OSD) at 24%, and Limbasi at 52%. The Limbasi facility's capacity is partially utilized for manufacturing raw materials and intermediates for other units, including Valthera. This backward integration is cited as a key competitive advantage for quality control and cost efficiency.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.